Gilead to end PhIII blood disorder trial for CD47 antibody magrolimab due to ‘futility’

Gilead will scrap one of three Phase III trials for magrolimab, the anti-CD47 drug at the heart of its $4.9 billion acquisition of Forty Seven three years ago, while carrying on with the other two.

In a late Friday statement, Gilead attributed the decision to “futility…
Click here to view original post

Advertisement — Advertise with Biotech Networks